Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer.
Marcus SchmidtHans LenhardArnd HoenigYvette ZimmermanJan KrijghMonique JansenHerjan Jt Coelingh BenninkPublished in: Journal of cancer research and clinical oncology (2020)
High doses of estetrol seem to be safe and are well tolerated during 12 weeks of treatment without dose-limiting toxicity and with anti-tumor effects in five of nine heavily treated patients with progressive, anti-estrogen resistant, advanced breast cancer.